Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-09-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于药品临床试验申请获受理的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of a clinical trial application for a new drug by the National Medical Products Administration (NMPA). It details the drug's basic information, research status, and potential impact on the company. The document is relatively short (1862 characters) and serves as a regulatory announcement about a specific event related to drug development, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-09-18 Chinese
关于参加2020年云南辖区上市公司投资者网上集体接待日的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor online collective reception day organized by regulatory and industry bodies. It mentions interaction with investors regarding the 2019 annual and 2020 half-year performance, governance, and sustainability, but does not contain any actual financial statements or detailed financial data. The document is short (658 characters) and serves as a notice of an event rather than a report or transcript. It does not fit categories like Annual Report, Interim Report, Call Transcript, or Investor Presentation. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about investor relations activities.
2020-09-16 Chinese
独立董事关于聘任胡振波先生为公司常务副总裁的独立意见
Board/Management Information Classification · 95% confidence The document is a formal independent opinion from the independent directors regarding the appointment of Mr. Hu Zhenbo as the company's Executive Vice President. It references governance rules and regulations but does not contain financial data, earnings, or report content. It is an announcement related to board/management changes, specifically the appointment of a senior executive. The document length is short and focused on management appointment, fitting the Board/Management Information category.
2020-09-09 Chinese
关于高级管理人员变动的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding changes in senior management, specifically the resignation of a vice president and the appointment of a new executive vice president. It includes details about the new appointee's background and confirms no conflicts of interest. There is no financial data, report, or regulatory filing referenced beyond the management change. This fits the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming the classification.
2020-09-09 Chinese
关于收到中国银行间市场交易商协会《接受注册通知书》的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group regarding the receipt of a registration acceptance notice from the China Interbank Market Dealers Association for the issuance of short-term financing bonds. It details the registration amount, validity period, and underwriting bank, and references prior announcements about the proposed issuance. The document is short (761 characters) and serves as an update on financing registration status rather than a full financial report or detailed financing activity. It does not contain financial statements or detailed analysis but is an official update on capital raising registration. Therefore, it fits best under Capital/Financing Update (CAP).
2020-09-02 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of using temporarily idle raised funds to purchase financial products. It includes specifics about the entrusted financial products, amounts, risk control measures, approval procedures, and financial impacts. The document is not a full financial report but an update on capital management activities related to fundraising proceeds. It does not contain comprehensive financial statements or quarterly/yearly financial results. The content fits the description of a Capital/Financing Update (CAP) as it provides updates on the use of raised funds and related financial product investments.
2020-08-31 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.